ReviewPLOS global public health2022
Financing malaria.
Review in PLOS global public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic review on the cost of seasonal malaria chemoprevention (SMC).Malaria journal · 2024Pooled it
- Housing modification to prevent malaria in Uganda: an analysis of costs, willingness to pay, and equity.Malaria journal · 2025Trial
- Entomological Adaptive Sampling Framework (EASF) for malaria vector surveillance: an economic evaluation of pilot implementation in Ghana and Mozambique.Malaria journal · 2026Article
- Addressing historical biases and the limits of biomedical commodities in vector-borne disease control in Africa.PLOS global public health · 2026Article
- Understanding barriers to effective malaria diagnosis and treatment: A mixed-methods study in Uganda, Nigeria, and Ivory Coast.PLOS global public health · 2026Article
- Vector Abundance and Genetic Diversity ofPublic health challenges · 2025Article
- Emerging Molecular Mechanisms in Malaria Pathogenesis and Novel Therapeutic Approaches: A Focus onBiomolecules · 2025Review
- Co-creation and application of a framework for the de-prioritization of urban communities during insecticide-treated bed net mass campaigns for malaria prevention and control in Kwara State, Nigeria.BMC global and public health · 2025Article
- Situational analysis of malaria in Cabo Verde: From endemic control to elimination, history, cases data and challenges ahead.PLOS global public health · 2025Article
- Unraveling the 'community effects' of interventions against malaria endemicity: a systematic scoping review.BMJ public health · 2024Article
- Examining malaria treatment and prevention spending efficiency in malaria-endemic countries, 2000-2020.Malaria journal · 2024Article
- Malaria epidemiology, surveillance and response for elimination in Lao PDR.Infectious diseases of poverty · 2024Review
- Factors impacting sustained coverage in the context of donor transitions: experience from Sri Lanka.Health policy and planning · 2024Article
- Ranking factors for coordinated supply chain management of ACTs in Uganda's general hospitals using the analytical hierarchy process.The journal of medicine accessArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The faltering of progress towards malaria elimination follows a plateauing in international financing since 2010. Despite calls for increased international financing, this will be hard to achieve. Both developed country donors and developing countries with malaria face severe fiscal constraints in expanding malaria funding in the next few years. Simply exhorting countries to spend more is unlikely to be successful, just as the Abuja declaration was not, and the developing countries with most malaria burden suffer from weaker economic growth and less capacity to increase domestic financing. One major prospect for substantial new financing is China, but this may depend on established funders yielding influence in the global financing architecture to China and other emerging economies. This argues for greater emphasis on spending available financing better, but improving the impact of international funding is not straightforward. It is associated with significant transaction costs for recipients, impairs the ability of the WHO to coordinate global efforts, and may pressure recipient countries to focus more on commodities and easy wins instead of investing in health systems and management capacity. While more should be done to mitigate these perverse effects, much of this is the unavoidable price of such generosity and the inevitable need for accountability to funders. Ultimately, countries must do more with their own spending, which is often under-counted, but usually far exceeds the international contribution. The experience of Sri Lanka, El Salvador, and China-three countries that eliminated malaria-provides two pointers. First, achieving early and widespread treatment of most malaria cases, which is not the case in much of high burden Africa, may be critical to sustain accelerated elimination. Second, such coverage requires health systems that prioritize access for all services and conditions. Public opinion surveys indicate that this is consistent with what much of the affected population wants, prioritizes, and is willing to finance through higher taxes, which points to weaknesses in accountability of policy to people. International funders could do better to heed what affected populations want and let local partners be responsive to their own public's preferences.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.